Edition:
United States

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

3.69USD
3:59pm EST
Change (% chg)

$0.01 (+0.27%)
Prev Close
$3.68
Open
$3.78
Day's High
$3.78
Day's Low
$3.60
Volume
42,543
Avg. Vol
124,295
52-wk High
$8.55
52-wk Low
$2.62

Latest Key Developments (Source: Significant Developments)

Adverum Biotechnologies Q2 Loss Per Share $0.30
Wednesday, 8 Aug 2018 04:05pm EDT 

Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.30.Q2 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.REMAIN ON TRACK TO DELIVER ON GOALS IN SECOND HALF OF YEAR FOR THREE LEAD GENE THERAPIES.SECURED A NEW FACILITY TO OCCUPY IN SECOND HALF OF NEXT YEAR.  Full Article

Adverum Biotechnologies Provides 2018 Outlook
Thursday, 4 Jan 2018 09:00am EST 

Jan 4 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES 2018 OUTLOOK.ADVERUM BIOTECHNOLOGIES INC - ADVERUM'S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017..ADVERUM BIOTECHNOLOGIES INC - CURRENT CASH POSITION IS EXPECTED TO FUND THREE LEAD GENE THERAPY PROGRAMS THROUGH END OF 2019.ADVERUM - PLAN TO SUBMIT 2 INVESTIGATIONAL NDA WITH FDA IN H2 2018, FOR ADVM-022 IN WET AMD, ADVM-053 IN HEREDITARY ANGIOEDEMA.  Full Article

Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies
Wednesday, 6 Dec 2017 05:37pm EST 

Dec 6 (Reuters) - Adverum Biotechnologies Inc ::HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING.  Full Article

Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial
Tuesday, 5 Dec 2017 09:00am EST 

Dec 5 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY.ADVERUM BIOTECHNOLOGIES INC - ‍COMPANY EXPECTS TO REPORT PRELIMINARY DATA IN SECOND HALF OF 2018​.  Full Article

‍Adage Capital Partners Reports A 5.55 Percent Passive Stake In Adverum Biotechnologies As Of Nov 17, 2017
Monday, 27 Nov 2017 10:51am EST 

Nov 27 (Reuters) - Adverum Biotechnologies Inc ::‍ADAGE CAPITAL PARTNERS GP, L.L.C REPORTS A 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF NOVEMBER 17, 2017 - SEC FILING​.  Full Article

Adverum Biotechnologies posts Q3 loss of $0.32 per share
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Adverum Biotechnologies Inc :Adverum biotechnologies reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.32.Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Adverum biotechnologies - ‍cash, cash equivalents,marketable securities were $186.6 million as of sept 30, 2017, versus $197.4 million as of june 30, 2017 ​.Adverum biotechnologies - ‍current cash position expected to fund 3 lead gene therapy programs through end of 2019.  Full Article

Adverum Biotechnologies files for mixed shelf of up to $150 mln
Thursday, 10 Aug 2017 05:32pm EDT 

Aug 10 (Reuters) - Adverum Biotechnologies Inc -:Adverum Biotechnologies Inc files for mixed shelf of up to $150 million - ‍​sec filing.  Full Article